FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2321810802> ?p ?o ?g. }

• W2321810802 endingPage "2806" @default.
• W2321810802 startingPage "2796" @default.
• W2321810802 abstract "The urokinase-type plasminogen activator receptor (uPAR) is implicated in cancer invasion and metastatic development in prostate cancer and provides therefore an attractive molecular target for both imaging and therapy. In this study, we provide the first in vivo data on an antimetastatic effect of uPAR radionuclide targeted therapy in such lesions and show the potential of uPAR positron emission tomography (PET) imaging for identifying small foci of metastatic cells in a mouse model of disseminating human prostate cancer. Two radiolabeled ligands were generated in high purity and specific activity: a uPAR-targeting probe (177Lu-DOTA-AE105) and a nonbinding control (177Lu-DOTA-AE105mut). Both uPAR flow cytometry and ELISA confirmed high expression levels of the target uPAR in PC-3M-LUC2.luc cells, and cell binding studies using 177Lu-DOTA-AE105 resulted in a specific binding with an IC50 value of 100 nM in a competitive binding experiment. In vivo, uPAR targeted radionuclide therapy significantly reduced the number of metastatic lesions in the disseminated metastatic prostate cancer model, when compared to vehicle and nontargeted 177Lu groups (p < 0.05) using bioluminescence imaging. Moreover, we found a significantly longer metastatic-free survival, with 65% of all mice without any disseminated metastatic lesions present at 65 days after first treatment dose (p = 0.047). In contrast, only 30% of all mice in the combined control groups treated with 177Lu-DOTA-AE105mut or vehicle were without metastatic lesions. No treatment-induced toxicity was observed during the study as evaluated by observing animal weight and H&E staining of kidney tissue (dose-limiting organ). Finally, uPAR PET imaging using 64Cu-DOTA-AE105 detected all small, disseminated metastatic foci when compared with bioluminescence imaging in a cohort of animals during the treatment study. In conclusion, uPAR targeted radiotherapy resulted in a significant reduction in the number of metastatic lesions in a human metastatic prostate cancer model. Furthermore, we have provided the first evidence of the potential for identification of small metastatic lesions using uPAR PET imaging in disseminated prostate cancer, illustrating the promising strategy of uPAR theranostics in prostate cancer." @default.
• W2321810802 created "2016-06-24" @default.
• W2321810802 creator A5024551500 @default.
• W2321810802 creator A5042958651 @default.
• W2321810802 creator A5044660787 @default.
• W2321810802 creator A5071117617 @default.
• W2321810802 creator A5071426519 @default.
• W2321810802 creator A5085326783 @default.
• W2321810802 creator A5089128595 @default.
• W2321810802 date "2014-07-01" @default.
• W2321810802 modified "2023-10-06" @default.
• W2321810802 title "uPAR Targeted Radionuclide Therapy with ¹⁷⁷Lu-DOTA-AE105 Inhibits Dissemination of Metastatic Prostate Cancer" @default.
• W2321810802 cites W1811441310 @default.
• W2321810802 cites W1823812337 @default.
• W2321810802 cites W1965087944 @default.
• W2321810802 cites W1969852115 @default.
• W2321810802 cites W1971944129 @default.
• W2321810802 cites W1973717257 @default.
• W2321810802 cites W1977264221 @default.
• W2321810802 cites W1977288750 @default.
• W2321810802 cites W1980901401 @default.
• W2321810802 cites W1984562763 @default.
• W2321810802 cites W2000340774 @default.
• W2321810802 cites W2001335554 @default.
• W2321810802 cites W2003844587 @default.
• W2321810802 cites W2028394303 @default.
• W2321810802 cites W2044141048 @default.
• W2321810802 cites W2047520474 @default.
• W2321810802 cites W2057734107 @default.
• W2321810802 cites W2060695118 @default.
• W2321810802 cites W2061339970 @default.
• W2321810802 cites W2064911312 @default.
• W2321810802 cites W2065727101 @default.
• W2321810802 cites W2065791048 @default.
• W2321810802 cites W2066340025 @default.
• W2321810802 cites W2068678479 @default.
• W2321810802 cites W2069846304 @default.
• W2321810802 cites W2079241416 @default.
• W2321810802 cites W2108780137 @default.
• W2321810802 cites W2109438520 @default.
• W2321810802 cites W2109850844 @default.
• W2321810802 cites W2117793166 @default.
• W2321810802 cites W2129452239 @default.
• W2321810802 cites W2141454098 @default.
• W2321810802 cites W2142252428 @default.
• W2321810802 cites W2143686200 @default.
• W2321810802 cites W2146367576 @default.
• W2321810802 cites W2148524882 @default.
• W2321810802 cites W2149385130 @default.
• W2321810802 cites W2154506800 @default.
• W2321810802 cites W2167077736 @default.
• W2321810802 cites W2170014976 @default.
• W2321810802 cites W260014646 @default.
• W2321810802 cites W4234937677 @default.
• W2321810802 cites W68959763 @default.
• W2321810802 doi "https://doi.org/10.1021/mp500177c" @default.
• W2321810802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24955765" @default.
• W2321810802 hasPublicationYear "2014" @default.
• W2321810802 type Work @default.
• W2321810802 sameAs 2321810802 @default.
• W2321810802 citedByCount "29" @default.
• W2321810802 countsByYear W23218108022015 @default.
• W2321810802 countsByYear W23218108022016 @default.
• W2321810802 countsByYear W23218108022017 @default.
• W2321810802 countsByYear W23218108022019 @default.
• W2321810802 countsByYear W23218108022020 @default.
• W2321810802 countsByYear W23218108022021 @default.
• W2321810802 countsByYear W23218108022022 @default.
• W2321810802 countsByYear W23218108022023 @default.
• W2321810802 crossrefType "journal-article" @default.
• W2321810802 hasAuthorship W2321810802A5024551500 @default.
• W2321810802 hasAuthorship W2321810802A5042958651 @default.
• W2321810802 hasAuthorship W2321810802A5044660787 @default.
• W2321810802 hasAuthorship W2321810802A5071117617 @default.
• W2321810802 hasAuthorship W2321810802A5071426519 @default.
• W2321810802 hasAuthorship W2321810802A5085326783 @default.
• W2321810802 hasAuthorship W2321810802A5089128595 @default.
• W2321810802 hasConcept C104317684 @default.
• W2321810802 hasConcept C111335760 @default.
• W2321810802 hasConcept C121608353 @default.
• W2321810802 hasConcept C126322002 @default.
• W2321810802 hasConcept C142724271 @default.
• W2321810802 hasConcept C150903083 @default.
• W2321810802 hasConcept C161997846 @default.
• W2321810802 hasConcept C185592680 @default.
• W2321810802 hasConcept C203014093 @default.
• W2321810802 hasConcept C207001950 @default.
• W2321810802 hasConcept C2779679481 @default.
• W2321810802 hasConcept C2779931791 @default.
• W2321810802 hasConcept C2780192828 @default.
• W2321810802 hasConcept C2781230642 @default.
• W2321810802 hasConcept C2989005 @default.
• W2321810802 hasConcept C2993559085 @default.
• W2321810802 hasConcept C502942594 @default.
• W2321810802 hasConcept C54009773 @default.
• W2321810802 hasConcept C553184892 @default.
• W2321810802 hasConcept C55493867 @default.
• W2321810802 hasConcept C56219504 @default.

• next